The Drug-Induced Respiratory Disease Website and App
Frequency - Incidence
Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases
Evidence level/grade
Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic
Fat/oil embolism - The FES embolism syndrome
Publications
Risk factors for the development of pulmonary oil embolism after transcatheter arterial chemoembolization of hepatic tumors.
Anti-cancer drugs. 2014;25(8):976-81
Cerebral iodized lipid embolization via a pulmonary arteriovenous shunt: rare complication of transcatheter arterial embolization for hepatocellular carcinoma.
World journal of surgical oncology. 2013;11:122
Pulmonary embolism: a fatal complication of arterial chemoembolization for advanced hepatocellular carcinoma.
Journal of pediatric surgery. 2005;40(10):1647-50
Hepatic tumors: predisposing factors for complications of transcatheter oily chemoembolization.
Radiology. 1996;198(1):33-40
Pulmonary oil embolism after transcatheter oily chemoembolization of hepatocellular carcinoma.
Radiology. 1993;187(3):689-93